Literature DB >> 25136130

Vaccines, new opportunities for a new society.

Rino Rappuoli1, Mariagrazia Pizza2, Giuseppe Del Giudice2, Ennio De Gregorio2.   

Abstract

Vaccination is the most effective medical intervention ever introduced and, together with clean water and sanitation, it has eliminated a large part of the infectious diseases that once killed millions of people. A recent study concluded that since 1924 in the United States alone, vaccines have prevented 40 million cases of diphtheria, 35 million cases of measles, and a total of 103 million cases of childhood diseases. A report from the World Health Organization states that today vaccines prevent 2.5 million deaths per year: Every minute five lives are saved by vaccines worldwide. Overall, vaccines have done and continue to do an excellent job in eliminating or reducing the impact of childhood diseases. Furthermore, thanks to new technologies, vaccines now have the potential to make an enormous contribution to the health of modern society by preventing and treating not only communicable diseases in all ages, but also noncommunicable diseases such as cancer and neurodegenerative disorders. The achievement of these results requires the development of novel technologies and health economic models able to capture not only the mere cost-benefit of vaccination, but also the value of health per se.

Entities:  

Keywords:  adjuvants; cost-effectiveness; immunotherapy; life expectancy; reverse vaccinology

Mesh:

Substances:

Year:  2014        PMID: 25136130      PMCID: PMC4151714          DOI: 10.1073/pnas.1402981111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it. 1766.

Authors:  Sally Blower; Daniel Bernoulli
Journal:  Rev Med Virol       Date:  2004 Sep-Oct       Impact factor: 6.989

2.  Meeting of the Strategic Advisory Group of Experts on immunization, April 2012--conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2012-05-25

3.  Vaccine economics: what price human life?

Authors:  John J Mekalanos
Journal:  Sci Transl Med       Date:  2013-09-25       Impact factor: 17.956

4.  Synthetic generation of influenza vaccine viruses for rapid response to pandemics.

Authors:  Philip R Dormitzer; Pirada Suphaphiphat; Daniel G Gibson; David E Wentworth; Timothy B Stockwell; Mikkel A Algire; Nina Alperovich; Mario Barro; David M Brown; Stewart Craig; Brian M Dattilo; Evgeniya A Denisova; Ivna De Souza; Markus Eickmann; Vivien G Dugan; Annette Ferrari; Raul C Gomila; Liqun Han; Casey Judge; Sarthak Mane; Mikhail Matrosovich; Chuck Merryman; Giuseppe Palladino; Gene A Palmer; Terika Spencer; Thomas Strecker; Heidi Trusheim; Jennifer Uhlendorff; Yingxia Wen; Anthony C Yee; Jayshree Zaveri; Bin Zhou; Stephan Becker; Armen Donabedian; Peter W Mason; John I Glass; Rino Rappuoli; J Craig Venter
Journal:  Sci Transl Med       Date:  2013-05-15       Impact factor: 17.956

Review 5.  Valuing vaccination.

Authors:  Till Bärnighausen; David E Bloom; Elizabeth T Cafiero-Fonseca; Jennifer Carroll O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  Oil-in-water emulsion adjuvant with influenza vaccine in young children.

Authors:  Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 8.  Prophylactic vaccines for prevention of prostate cancer.

Authors:  Rajesh K Naz; Briana Shiley
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

Review 10.  The challenge of emerging and re-emerging infectious diseases.

Authors:  David M Morens; Gregory K Folkers; Anthony S Fauci
Journal:  Nature       Date:  2004-07-08       Impact factor: 49.962

View more
  81 in total

Review 1.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Delivering vaccines to the people who need them most.

Authors:  Michèle Anne Barocchi; Rino Rappuoli
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

3.  Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations.

Authors:  Jean-Louis Palgen; Nicolas Tchitchek; André Rodriguez-Pozo; Quentin Jouhault; Hadjer Abdelhouahab; Nathalie Dereuddre-Bosquet; Vanessa Contreras; Frédéric Martinon; Antonio Cosma; Yves Lévy; Roger Le Grand; Anne-Sophie Beignon
Journal:  NPJ Vaccines       Date:  2020-03-19       Impact factor: 7.344

4.  The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Authors:  Megan Laudenbach; Federico Baruffaldi; Jeffrey S Vervacke; Mark D Distefano; Philip J Titcombe; Daniel L Mueller; Noah J Tubo; Thomas S Griffith; Marco Pravetoni
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

5.  Vaccines: science, health, longevity, and wealth.

Authors:  Rino Rappuoli
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-26       Impact factor: 11.205

Review 6.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 7.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

Review 8.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

9.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 10.  Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Authors:  Susanna Esposito; Paolo Bonanni; Stefania Maggi; Litjan Tan; Filippo Ansaldi; Pier Luigi Lopalco; Ron Dagan; Jean-Pierre Michel; Pierre van Damme; Jacques Gaillat; Roman Prymula; Timo Vesikari; Cristina Mussini; Uwe Frank; Albert Osterhaus; Lucia Pastore Celentano; Marta Rossi; Valentina Guercio; Gaetan Gavazzi
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.